Navigation Links
Genzyme Begins Major Expansion of Boston Manufacturing Facility
Date:9/18/2007

rks of art from the Expression of Hope exhibition, produced by people in Massachusetts and around the world living with lysosomal storage disorders. These patients were invited to create and submit a work of art that expressed their feelings of hope in the face of their struggles with a rare illness. The exhibition also features pieces created by artists from the Massachusetts College of Art, who spent time with patients and produced pieces representing the spirit of these individuals.

Allston Landing's more than 400 employees work around the clock, 365 days a year to ensure that the therapies produced there meet optimal quality standards. Genzyme recruits and trains residents from the local community for a wide range of jobs at the facility, including positions in manufacturing operations, facilities engineering, and quality operations.

The architect for the Allston expansion project is ARC/Architectural Resources Cambridge Inc. and the general contractor is Turner Construction Inc. The engineers are Clark, Richardson & Biskup, Careba Mott MacDonald, and Tetra Tech Rizzo. The project is expected to be completed in approximately two years.

As it has grown internationally, Genzyme has maintained its long-standing commitment to Massachusetts, where the company was founded in 1981. Genzyme has a large and growing presence in the state, which is home to nearly half of the company's approximately 10,000 employees. Genzyme recently completed its new 180,000 square-foot Science Center in Framingham, as well as a 55,000 square-foot expansion of its Waltham location, and the company continues to build its presence in Boston, Cambridge, and Westborough. Genzyme currently occupies more than 2 million square feet of space in Massachusetts. The company has facilities across the United States and in more than 30 countries around the world. Genzyme is conducting major expansion projects in Belgium, France, the United Kingdom, China, and the Netherlands.

Abo
'/>"/>

SOURCE Genzyme Corp.
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. Cytochroma settles lawsuit with Genzyme
2. Genzyme sues former Bone Care employees
3. Genzyme acquistion of Bone Care approved, significant impact forecast
4. DeForest biodiesel plant begins production
5. Deltanoid Pharmaceuticals begins phase II osteoporosis study
6. Prodesse begins clinical trials for flu virus detection
7. Closing the income gap begins with education
8. Corporate control begins with a strong board
9. Emerging game developer begins work on prototypes
10. GE begins human trials for cancer detection agent
11. Now the real work begins
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/20/2014)... The 6th Annual Arrowhead Personalized ... October 29-30 in San Francisco, CA. This year’s conference ... researchers and clinicians focused on addressing and solving the ... the twelve years since the sequencing of the human ... with pharmacogenetic information in the label and molecular diagnostics ...
(Date:8/20/2014)... your ear could improve the health of your heart, ... of Leeds used a standard TENS machine like those ... to the tragus, the small raised flap at the ... ear canal. , The stimulation changed the influence of ... nervous signals that can drive failing hearts too hard. ...
(Date:8/19/2014)... 2014 One of the major ... an inadequate vascular supply. Nutrient and gas transport ... is critical for successful regeneration and integration into ... deficiencies in vascularization and promote angiogenesis in a ... scaffold design and architecture, and enhancing scaffolds with ...
(Date:8/19/2014)... Pa. , Aug. 19, 2014 A ... has been nominated for a Centers for Disease Control ... addressing a major public health concern. ... System, is one of a team of researchers nominated ... Charles C. Shepard Science Award for Data Methods and ...
Breaking Biology Technology:6th Annual Personalized and Precision Medicine Conference Bringing Together Thought Leaders to Discuss Clinical Implementation, Dx Reimbursement, Big Data, and Sequencing 2'Tickling' your ear could be good for your heart 2Vascularization in Tissue Engineering Highlighted at 12th New Jersey Symposium on Biomaterials Science 2Geisinger investigator nominated for federal award 2Geisinger investigator nominated for federal award 3
... Jan. 9, 2012 Reportlinker.com announces ... is available in its catalogue: , ... Transplantation, Cord Blood Banking and Drug ... There is great interest ...
... Sequenom, Inc. (NASDAQ: SQNM ), a life ... of the Company,s 2011 performance and accomplishments, as well as ... Initial 2011 Performance Results ... for 2011 (unaudited). , Over 21,000 total prenatal and ...
... today that it has secured $47.5 million in Series ... financing along with existing investors OrbiMed Advisors, New Enterprise ... financing, Josh Bilenker, M.D., Partner at Aisling Capital, will ... round will support commercialization of the company,s Atlas™ System ...
Cached Biology Technology:Stem Cells: Worldwide Markets for Transplantation, Cord Blood Banking and Drug Development 2Stem Cells: Worldwide Markets for Transplantation, Cord Blood Banking and Drug Development 3Stem Cells: Worldwide Markets for Transplantation, Cord Blood Banking and Drug Development 4Stem Cells: Worldwide Markets for Transplantation, Cord Blood Banking and Drug Development 5Stem Cells: Worldwide Markets for Transplantation, Cord Blood Banking and Drug Development 6Sequenom Announces 2011 Operational Highlights and Early 2012 Outlook 2Sequenom Announces 2011 Operational Highlights and Early 2012 Outlook 3Sequenom Announces 2011 Operational Highlights and Early 2012 Outlook 4Roka Bioscience Secures $47.5 Million in Series D Financing 2
(Date:8/20/2014)... from the University of Tbingen, Arizona State University, the ... Public Health Institute (Swiss TPH) isolated Mycobacterium pinnipedii ... least 1000 years old. The pathogen is a relative ... occasionally causes disease in humans today. These researchers assume ... Peruvian coast. "The link to sea lions was unexpected" ...
(Date:8/20/2014)... that acral melanomas the rare type of skin cancer ... distinct from other more common types of skin cancer, according ... Pigment Cell & Melanoma Research . , Acral melanoma ... the feet, nail-beds and other hairless parts of the skin. ... by UV damage from the sun. , The team, from ...
(Date:8/20/2014)... and plastic bags could one day be made out ... scientists are now reporting. The novel process they developed ... with its agricultural and plastic waste problems, appear in ... Ilker S. Bayer and colleagues at the Italian Institute ... growing. In 2012, its production reached 288 million tons ...
Breaking Biology News(10 mins):Scientists learn more about rare skin cancer that killed Bob Marley 2
... , Cincinnati, (OH) - The International Rett Syndrome Foundation (IRSF) ... 18 new grants designed to study a variety of diverse ... and outcome measures for Rett syndrome. IRSF is the ... Rett syndrome research with the cumulative total of research spending ...
... German-based project is setting out to rescue biodiversity data at ... institutional databases, are kept in outdated digital storage systems, or ... Botanic Garden and Botanical Museum Berlin-Dahlem, provides a good example ... data. This is one of a set of data ...
... that is associated with the spread of cancer has won ... one of this year,s Kaye Innovation Awards at the university. ... of Prof. Chaim Gilon and Prof. Alexander Levitzki at the ... B (PKB, also called Akt). Since the activation of PKB ...
Cached Biology News:IRSF awards over $1.5 million for basic and translational research for Rett syndrome 2IRSF awards over $1.5 million for basic and translational research for Rett syndrome 3German research team targets 'at risk' data on biodiversity 2German research team targets 'at risk' data on biodiversity 3